MD3288940T2 - Azabenzimidazoli și utilizarea lor ca modulatori ai receptorilor AMPA - Google Patents

Azabenzimidazoli și utilizarea lor ca modulatori ai receptorilor AMPA

Info

Publication number
MD3288940T2
MD3288940T2 MDE20180234T MDE20180234T MD3288940T2 MD 3288940 T2 MD3288940 T2 MD 3288940T2 MD E20180234 T MDE20180234 T MD E20180234T MD E20180234 T MDE20180234 T MD E20180234T MD 3288940 T2 MD3288940 T2 MD 3288940T2
Authority
MD
Moldova
Prior art keywords
azabenzimidazoles
receptor modulators
ampa receptor
compounds
formula
Prior art date
Application number
MDE20180234T
Other languages
English (en)
Inventor
Cynthia G B Berry
Gang Chen
Fabrice Loic Jourdan
Terry Patrick Lebold
David Wei Lin
Pinon Miguel Angel Pena
Suchitra Ravula
Bradley M Savall
Devin M Swanson
Dongpei Wu
Wei Zhang
Michael K Ameriks
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of MD3288940T2 publication Critical patent/MD3288940T2/ro

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/02—Systems containing only non-condensed rings with a three-membered ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/04—Systems containing only non-condensed rings with a four-membered ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/06—Systems containing only non-condensed rings with a five-membered ring
    • C07C2601/08—Systems containing only non-condensed rings with a five-membered ring the ring being saturated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/14—The ring being saturated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/16—Systems containing only non-condensed rings with a six-membered ring the ring being unsaturated

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Sunt furnizaţi aici compuşi cu Formula (I), şi săruri acceptabile farmaceutic, N-oxizi, sau solvaţi ai acestora,Sunt de asemenea furnizate aici compoziţii farmaceutice care cuprind compuşii cu Formula (I) şi metode de utilizare a compuşilor cu Formula (I).
MDE20180234T 2015-04-29 2016-04-28 Azabenzimidazoli și utilizarea lor ca modulatori ai receptorilor AMPA MD3288940T2 (ro)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562154313P 2015-04-29 2015-04-29
PCT/US2016/029801 WO2016176460A1 (en) 2015-04-29 2016-04-28 Azabenzimidazoles and their use as ampa receptor modulators

Publications (1)

Publication Number Publication Date
MD3288940T2 true MD3288940T2 (ro) 2021-08-31

Family

ID=56008859

Family Applications (1)

Application Number Title Priority Date Filing Date
MDE20180234T MD3288940T2 (ro) 2015-04-29 2016-04-28 Azabenzimidazoli și utilizarea lor ca modulatori ai receptorilor AMPA

Country Status (39)

Country Link
US (4) US11312712B2 (ro)
EP (3) EP4144736A1 (ro)
JP (2) JP6800886B2 (ro)
KR (2) KR20170140382A (ro)
CN (1) CN107835814B (ro)
AR (1) AR104447A1 (ro)
AU (2) AU2016255434C1 (ro)
BR (2) BR112017023147B1 (ro)
CA (1) CA2983826A1 (ro)
CO (1) CO2017011017A2 (ro)
CR (1) CR20170484A (ro)
CY (1) CY1124059T1 (ro)
DK (1) DK3288940T5 (ro)
EA (1) EA033281B1 (ro)
EC (1) ECSP17074645A (ro)
ES (1) ES2865330T3 (ro)
GT (1) GT201700231A (ro)
HK (1) HK1252249A1 (ro)
HR (1) HRP20210403T1 (ro)
HU (1) HUE053943T2 (ro)
IL (1) IL254848B (ro)
JO (1) JO3654B1 (ro)
LT (1) LT3288940T (ro)
MA (1) MA41988B1 (ro)
MD (1) MD3288940T2 (ro)
MX (1) MX2017013886A (ro)
MY (1) MY194104A (ro)
NI (1) NI201700129A (ro)
PH (1) PH12017501816A1 (ro)
PL (1) PL3288940T3 (ro)
PT (1) PT3288940T (ro)
RS (1) RS61688B1 (ro)
SG (1) SG11201708190UA (ro)
SI (1) SI3288940T1 (ro)
TW (1) TWI706952B (ro)
UA (1) UA120304C2 (ro)
UY (1) UY36654A (ro)
WO (1) WO2016176460A1 (ro)
ZA (1) ZA201708065B (ro)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3288945B1 (en) * 2015-04-29 2019-09-18 Janssen Pharmaceutica NV Imidazopyrazines and pyrazolopyrimidines and their use as ampa receptor modulators
CN107383004B (zh) * 2017-07-05 2020-04-17 浙江大学 2-氨基咪唑并吡啶类衍生物及制备和应用
EP3679027A1 (en) 2017-09-04 2020-07-15 C4 Therapeutics, Inc. Dihydrobenzimidazolones
JP7250687B2 (ja) * 2017-10-06 2023-04-03 武田薬品工業株式会社 複素環化合物
SI3860998T1 (sl) 2018-10-05 2024-06-28 Annapurna Bio Inc. Spojine in sestavki za zdravljenje stanj, povezanih z aktivnostjo apj-receptorja
JP2022510501A (ja) * 2018-10-30 2022-01-26 リペア セラピューティクス インコーポレイテッド 化合物、医薬組成物、ならびに化合物の調製方法及びａｔｒキナーゼ阻害剤としてのその使用方法
EP4003993A4 (en) * 2019-07-22 2023-01-18 Repare Therapeutics Inc. SUBSTITUTED 2-MORPHOLINOPYRIDE DERIVATIVES AS ATR KINASE INHIBITORS
EP4263523A2 (en) * 2020-12-16 2023-10-25 IFM Due, Inc. Compounds and compositions for treating conditions associated with sting activity
CN114591338B (zh) * 2022-03-31 2023-05-09 苏州欧康维视生物科技有限公司 一种Syk和VEGFR2双靶点抑制剂的制备方法及其用途
CN115304599A (zh) * 2022-09-20 2022-11-08 浙大宁波理工学院 一种3-溴-6-异丙基-1氢-哌咯[2，3-b]并吡啶及其制备方法

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS55167282A (en) 1979-06-12 1980-12-26 Fujisawa Pharmaceut Co Ltd Piperazine derivative or its salt and its preparation
CN1051313A (zh) 1990-11-07 1991-05-15 鞍山市振东工业尼龙厂 尼龙球磨罐及其热装工艺
GB9210400D0 (en) * 1992-05-15 1992-07-01 Merck Sharp & Dohme Therapeutic agents
TW251284B (ro) * 1992-11-02 1995-07-11 Pfizer
CN1067386C (zh) * 1994-02-10 2001-06-20 辉瑞大药厂 作为苯并二氮杂䓬受体位的兴奋剂和拮抗药的5－杂芳基吲哚衍生物
US5565483A (en) 1995-06-07 1996-10-15 Bristol-Myers Squibb Company 3-substituted oxindole derivatives as potassium channel modulators
UA54403C2 (uk) 1996-10-01 2003-03-17 Н'Юросерч А/С Похідні індол-2,3-діон-3-оксиму, фармацевтична композиція, спосіб лікування розладу чи захворювання ссавців, у тому числі людини та спосіб одержання похідних індол-2,3-діон-3-оксиму
DE19812331A1 (de) 1998-03-20 1999-09-23 Merck Patent Gmbh Piperidinderivate
EP1100504A2 (en) * 1998-07-02 2001-05-23 Eisai Co., Ltd. Pharmaceutical compositions and their uses for treatment of demyelinating disorders
JP2002533360A (ja) 1998-12-31 2002-10-08 スージェン・インコーポレーテッド 蛋白質キナーゼ活性を調節するためおよび癌の化学療法において用いるための３−ヘテロアリーリデニル−２−インドリノン化合物
GB0018473D0 (en) 2000-07-27 2000-09-13 Merck Sharp & Dohme Therapeutic agents
AU2001282865A1 (en) 2000-08-11 2002-02-25 Eli Lilly And Company Heterocyclic sulfonamide derivatives
US6548576B1 (en) 2001-11-07 2003-04-15 Bourns, Inc. Epoxy formulation adapted to be used in conjunction with no-lead solder in electronic components
GT200500185A (es) 2004-08-09 2006-04-10 Moduladores del receptor de progesterona que comprenden derivados de pirrol-oxindol y sus usos
CN101052640B (zh) * 2004-09-03 2011-05-11 默克雪兰诺有限公司 吡啶亚甲基唑烷酮类及其作为磷酸肌醇抑制剂的用途
NZ566508A (en) 2005-09-30 2011-07-29 Glaxo Group Ltd Benzimidazole derivatives which have activity at M1 receptor and their uses in medicine
WO2007135529A2 (en) 2006-05-23 2007-11-29 Pfizer Products Inc. Azabenzimidazolyl compounds as mglur2 potentiators
ATE502675T1 (de) 2006-11-03 2011-04-15 Glaxo Group Ltd Verbindungen, die den ampa-rezeptor verstärken, und deren anwendung in der medizin
WO2008113795A1 (en) 2007-03-20 2008-09-25 Glaxo Group Limited Compounds which potentiate ampa receptor and uses thereof in medicine
GB0711089D0 (en) 2007-06-08 2007-07-18 Glaxo Group Ltd Compounds
GB0716292D0 (en) 2007-08-21 2007-09-26 Biofocus Dpi Ltd Imidazopyrazine compounds
WO2009067607A2 (en) 2007-11-20 2009-05-28 Memory Pharmaceuticals Corporation Combinations of pde4 inhibitors and antipsychotics for the treatment of psychotic disorders
KR20100094554A (ko) * 2007-12-06 2010-08-26 쉐링 코포레이션 감마 세크레타제 조절인자
TW201012803A (en) * 2008-06-06 2010-04-01 Organon Nv Heterocyclic derivatives
US20110312938A1 (en) * 2008-06-30 2011-12-22 Ironwood Pharmaceuticals, Inc. Pyrrolopyridine Carboxylic Acid Derivatives
GB0822425D0 (en) 2008-12-09 2009-01-14 Glaxo Group Ltd Compounds
GB0822981D0 (en) 2008-12-17 2009-01-21 Summit Corp Plc Compounds for treatment of duchenne muscular dystrophy
WO2011056985A2 (en) 2009-11-04 2011-05-12 Gilead Sciences, Inc. Substituted heterocyclic compounds
EP2579717A4 (en) * 2010-06-09 2013-12-11 Merck Sharp & Dohme POSITIVE ALLOSTERIC MODULATORS OF MGLUR2
CN103180326B (zh) 2010-08-10 2015-06-10 武田药品工业株式会社 杂环化合物及其用途
EP2603079B1 (en) 2010-08-12 2018-09-19 Merck Sharp & Dohme Corp. Positive allosteric modulators of mglur2
JP6014155B2 (ja) 2011-10-31 2016-10-25 ゼノン・ファーマシューティカルズ・インコーポレイテッドＸｅｎｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃ． ビアリールエーテルスルホンアミドおよび治療剤としてのそれらの使用
WO2013130501A1 (en) * 2012-03-01 2013-09-06 The Board Of Regents Of The University Of Texas System Bivalent ampa receptor positive allosteric modulators
GB201205669D0 (en) * 2012-03-30 2012-05-16 Agency Science Tech & Res Bicyclic heterocyclic derivatives as mnk2 and mnk2 modulators and uses thereof
JO3225B1 (ar) * 2012-11-27 2018-03-08 Lilly Co Eli 6-((s)-1-{1-[5-(2-هيدروكسي-إيثوكسي)-بيريدين-2-يل]-1h-بيرازول-3-يل}إيثيل)-3h-1 ، 3-بنزو ثيازول-2- أون باعتباره مضاد مستقبل ampa يعتمد على tarp- جاما 8
MA38333A1 (fr) 2013-02-19 2017-02-28 Pfizer Composés d'azabenzimidazole en tant qu'inhibiteurs d'isozymes pde4 pour le traitement de troubles du snc et d'autres affections

Also Published As

Publication number Publication date
SG11201708190UA (en) 2017-11-29
EP3901153A1 (en) 2021-10-27
KR20240017991A (ko) 2024-02-08
CN107835814A (zh) 2018-03-23
JP6800886B2 (ja) 2020-12-16
CN107835814B (zh) 2021-07-23
AR104447A1 (es) 2017-07-19
AU2020210231B2 (en) 2021-07-22
CO2017011017A2 (es) 2018-03-20
US20230114165A1 (en) 2023-04-13
LT3288940T (lt) 2021-05-10
BR112017023147B1 (pt) 2024-04-30
RS61688B1 (sr) 2021-05-31
JO3654B1 (ar) 2020-08-27
PH12017501816A1 (en) 2018-04-23
BR112017023147A2 (pt) 2018-07-10
MA41988B1 (fr) 2021-03-31
AU2016255434C1 (en) 2021-09-23
UA120304C2 (uk) 2019-11-11
TWI706952B (zh) 2020-10-11
US20180118740A1 (en) 2018-05-03
EA201792374A1 (ru) 2018-05-31
AU2020210231A1 (en) 2020-08-20
IL254848A0 (en) 2017-12-31
IL254848B (en) 2021-01-31
US20230110576A1 (en) 2023-04-13
KR20170140382A (ko) 2017-12-20
CA2983826A1 (en) 2016-11-03
WO2016176460A1 (en) 2016-11-03
HK1252249A1 (zh) 2019-05-24
MY194104A (en) 2022-11-11
CY1124059T1 (el) 2022-05-27
ZA201708065B (en) 2019-09-25
EP4144736A1 (en) 2023-03-08
ES2865330T3 (es) 2021-10-15
BR122023023802A2 (pt) 2023-12-26
JP7026194B2 (ja) 2022-02-25
EA033281B1 (ru) 2019-09-30
TW201708217A (zh) 2017-03-01
AU2016255434A1 (en) 2017-10-26
EP3288940A1 (en) 2018-03-07
SI3288940T1 (sl) 2021-07-30
GT201700231A (es) 2018-12-20
DK3288940T3 (da) 2021-05-25
PL3288940T3 (pl) 2021-07-12
HRP20210403T1 (hr) 2021-10-29
PT3288940T (pt) 2021-04-30
DK3288940T5 (da) 2021-09-20
HUE053943T2 (hu) 2021-08-30
MA41988A (fr) 2018-07-03
JP2018518462A (ja) 2018-07-12
EP3288940B1 (en) 2021-02-24
MX2017013886A (es) 2018-03-12
UY36654A (es) 2016-10-31
US20210284641A1 (en) 2021-09-16
ECSP17074645A (es) 2018-02-28
US11312712B2 (en) 2022-04-26
NI201700129A (es) 2019-05-10
EP3288940B9 (en) 2021-07-21
CR20170484A (es) 2018-02-26
NZ736057A (en) 2023-08-25
AU2016255434B2 (en) 2020-05-14
JP2021042230A (ja) 2021-03-18

Similar Documents

Publication Publication Date Title
MD3288940T2 (ro) Azabenzimidazoli și utilizarea lor ca modulatori ai receptorilor AMPA
MD3313817T2 (ro) Derivați biciclici, un procedeu pentru prepararea lor și compozițiile farmaceutice care îi conțin
MX2016016593A (es) Nuevos derivados de aminoalquibenzotiazepina y usos de los mismos.
TR201904658T4 (tr) Bisiklik füzyonla birleştirilmiş heteroaril veya aril bileşikleri ve bunların ırak4 inhibitörleri olarak kullanımları.
MD3313850T2 (ro) Noi derivaţi de aminoacizi, procedeu pentru prepararea acestora şi compoziţii farmaceutice care îi conţin
WO2016011390A8 (en) Irak4 inhibiting agents
MX2017013877A (es) Compuestos de benzimidazolona y benzotiazolona y su uso como moduladores del receptor ampa.
MD3319612T2 (ro) Oxisteroli și metode de utilizare a acestora
EA201791304A1 (ru) Производные изохинолина для лечения вич
EA201201263A1 (ru) Фармацевтическая композиция, содержащая этексилат дабигатрана
PH12019501639A1 (en) Jaki selective inhibitors
PH12016501624A1 (en) 1,2-substituted cyclopentanes as orexin receptor antagonists
MA39956A (fr) Analogues du benzomorphane et leur utilisation
NZ729252A (en) Methyl-and trifluoromethyl-substituted pyrrolopyridine modulators of rorc2 and methods of use thereof
EA201790627A1 (ru) СТИМУЛЯТОРЫ рГЦ
CY1124251T1 (el) Παραγωγα καρβοξαμιδιου
EA201201202A1 (ru) Пероральная фармацевтическая композиция, содержащая этексилат дабигатрана
MD3303331T2 (ro) Modulatori alosterici pozitivi ai receptorilor muscarinici M1
MD3265459T2 (ro) Compuși amidici în calitate de agoniști ai receptorilor 5-HT4
MX2018015872A (es) Derivados de benzodioxano y su uso farmaceutico.
ZA201903291B (en) Fused bicylic pyridine compounds and their use as ampa receptor modulators
UY36117A (es) Composiciones farmacéuticas para el tratamiento de enfermedades infecciosas.
EA201691796A1 (ru) П-замещенные асимметричные мочевины и их применение в медицине
PH12016501625A1 (en) Substituted cyclopentanes, tetrahydrofuranes and pyrrolidines as orexin receptor antagonists
EA201991045A1 (ru) Конденсированные азагетероциклические соединения и их применение в качестве модуляторов ampa-рецептора